Investigation of polyomaviruses replication in pediatric patients with nephropathy receiving rituximab

Journal of Medical Virology

Volumn 84, Issue 9, 2012, Pages 1464-1470

  Delbue, Serena ^a   Ferraresso, Mariano ^b   Elia, Francesca ^a   Belingheri, Mirco ^c   Carloni, Camilla ^b   Signorini, Lucia ^b   Carluccio, Silvia ^b   Dallari, Simone ^b   Ghio, Luciana ^c   Ferrante, Pasquale ^b,d  

^a Health Science Foundation   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Clinica Pediatrica De Marchi   (Italy)

^d Clinical Institute Città Studi ICCS   (Italy)

Author keywords

Children; Monoclonal antibody; Nephrotic syndromes; Polyomavirus

Indexed keywords

RITUXIMAB; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; BK VIRUS; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; KIDNEY DISEASE; LONGITUDINAL STUDY; MALE; NEPHROTIC SYNDROME; POLYOMA VIRUS; PRESCHOOL CHILD; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; URINALYSIS; VIRUS LOAD; VIRUS REPLICATION;

ADOLESCENT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BK VIRUS; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; IMMUNOLOGIC FACTORS; JC VIRUS; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MOLECULAR TYPING; NEPHROTIC SYNDROME; POLYOMAVIRUS INFECTIONS; REGULATORY SEQUENCES, NUCLEIC ACID; SEQUENCE ANALYSIS, DNA; TUMOR VIRUS INFECTIONS; VIRAL PROTEINS; VIRUS ACTIVATION; VIRUS REPLICATION;

BK POLYOMAVIRUS; JC POLYOMAVIRUS; POLYOMAVIRUS;

EID: 84864147862     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23339     Document Type: Article

References (55)

1. Agostini HT, Ryschkewitsch CF, Stoner GL. 1996. Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals. J Clin Microbiol 34: 159-164.
2. Agostini HT, Deckhut A, Jobes DV, Girones R, Schlunck G, Prost MG, Frias C, Perez-Trallero E, Ryschkewitsch CF, Stoner GL. 2001a. Genotypes of JC virus in East, Central and Southwest Europe. J Gen Virol 82: 1221-1231.
3. Agostini HT, Jobes DV, Stoner GL. 2001b. Molecular evolution and epidemiology of JC virus. In: Khalili K, Stoner GL, editors. Human polyomaviruses. Molecular and clinical perspectives. New York: Wiley-Liss, pp 491-526.
4. Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, Barista I. 2007. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 48: 1307-1312.
5. Alausa M, Almagro U, Siddiqi N, Zuiderweg R, Medipalli R, Hariharan S. 2005. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab. Clin Transplant 19: 137-140.
6. Ault GS, Stoner GL. 1993. Human polyomavirus JC promoter/enhancer rearrangement patterns from progressive multifocal leukoencephalopathy brain are unique derivatives of a single archetypal structure. J Gen Virol 74: 1499-1507.
7. Becker YT, Becker BN, Pirsch JD, Sollinger HW. 2004. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 4: 996-1001.
8. Benz K, Dotsch J, Rascher W, Stachel D. 2004. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19: 794-797.
9. Berger JR, Scott G, Albrecht J, Belman AL, Tornatore C, Major EO. 1992. Progressive multifocal leukoencephalopathy in HIV-1-infected children. AIDS 6: 837-841.
10. Boldorini R, Allegrini S, Miglio U, Nestasio I, Paganotti A, Veggiani C, Monga G, Pietropaolo V. 2010. BK virus sequences in specimens from aborted fetuses. J Med Virol 82: 2127-2132.
11. Brown DW, Gardner SD, Gibson PE, Field AM. 1984. BK virus specific IgM responses in cord sera, young children and healthy adults detected by RIA. Arch Virol 82: 149-160.
12. Calabrese LH, Molloy ES. 2008. Progressive multifocal leucoencephalopathy in the rheumatic diseases: Assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 67: iii64-iii65.
13. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL. 2009. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113: 4834-4840.
14. Ciappi S, Azzi A, De Santis R, Leoncini F, Sterrantino G, Mazzotta F, Mecocci L. 1999. Archetypal and rearranged sequences of human polyomavirus JC transcription control region in peripheral blood leukocytes and in cerebrospinal fluid. J Gen Virol 80: 1017-1023.
15. Coiffier B. 2006. Treatment of non-Hodgkin's lymphoma: A look over the past decade. Clin Lymphoma Myeloma 7: S7-S13.
16. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. 2004. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-Year follow-up. J Clin Oncol 22: 4711-4716.
17. Dass S, Vital EM, Emery P. 2006. Rituximab: Novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Expert Opin Pharmacother 7: 2559-2570.
18. Delbue S, Sotgiu G, Fumagalli D, Valli M, Borghi E, Mancuso R, Marchioni E, Maserati R, Ferrante P. 2005a. A case of a progressive multifocal leukoencephalopathy patient with four different JC virus transcriptional control region rearrangements in cerebrospinal fluid, blood, serum, and urine. J Neurovirol 11: 51-57.
19. Delbue S, Pagani E, Guerini FR, Agliardi C, Mancuso R, Borghi E, Rossi F, Boldorini R, Veggiani C, Car PG, Ferrante P. 2005b. Distribution, characterization and significance of polyomavirus genomic sequences in tumors of the brain and its covering. J Med Virol 77: 447-454.
20. Elsner C, Dorries K. 1992. Evidence of human polyomavirus BK and JC infection in normal brain tissue. Virology 191: 72-80.
21. Ferrante P, Caldarelli-Stefano R, Omodeo-Zorini E, Vago L, Boldorini R, Costanzi G. 1995. PCR detection of JC virus DNA in brain tissue from patients with and without progressive multifocal leukoencephalopathy. J Med Virol 47: 219-225.
22. Flaegstad T, Traavik T, Kristiansen BE. 1986. Age-dependent prevalence of BK virus IgG and IgM antibodies measured by enzyme-linked immunosorbent assays (ELISA). J Hyg (Lond) 96: 523-528.
23. Flaegstad T, Sundsfjord A, Arthur RR, Pedersen M, Traavik T, Subramani S. 1991. Amplification and sequencing of the control regions of BK and JC virus from human urine by polymerase chain reaction. Virology 180: 553-560.
24. Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F. 2008. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: A multicentric series of 22 cases. Pediatr Nephrol 23: 1269-1279.
25. Ikegaya H, Saukko PJ, Tertti R, Metsarinne KP, Carr MJ, Crowley B, Sakurada K, Zheng HY, Kitamura T, Yogo Y. 2006. Identification of a genomic subgroup of BKpolyomavirus spread in European populations. J Gen Virol 87: 3201-3208.
26. Jayne D. 2008. Role of rituximab therapy in glomerulonephritis. J Am Soc Nephrol 21: 14-17.
27. Jensen PN, Major EO. 2001. Review. A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the noncoding regulatory region. J Neurovirol 7: 280-287.
28. Jin L, Gibson PE, Knowles WA, Clewley JP. 1993. BK virus antigenic variants: Sequence analysis within the capsid VP1 epitope. J Med Virol 39: 50-56.
29. Johnsen JI, Seternes OM, Johansen T, Moens U, Mäntyjärvi R, Traavik T. 1995. Subpopulations of non-coding control region variants within a cell culture-passaged stock of BK virus: Sequence comparisons and biological characteristics. J Gen Virol 76: 1571-1581.
30. Kelesidis T, Daikos G, Boumpas D, Tsiodras S. 2011. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 15: e2-e16.
31. Kwok S, Higuchi R. 1989. Avoiding false positives with PCR. Nature 339: 237-238.
32. Lazdina U, Alheim M, Nystrom J, Hultgren C, Borisova G, Sominskaya I, Pumpens P, Peterson DL, Milich DR, Sällberg M. 2003. Priming of cytotoxic T cell responses toexogenous hepatitis B virus core antigen is B cell dependent. J Gen Virol 84: 139-146.
33. Liptai Z, Papp E, Barsi P, Mihály I, Szalai E, Csomor J, Jelenik Z. 2007. Progressive multifocal leukoencephalopathy in an HIV-infected child. Neuropediatrics 38: 32-35.
34. Lund FE, Hollifield M, Schuer K, Lines JL, Randall TD, Garvy BA. 2006. B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol 176: 6147-6154.
35. Moens U, Johansen T, Johnsen JI, Seternes OM, Traavik T. 1995. Noncoding control region of naturally occurring BK virus variants: Sequence comparison and functional analysis. Virus Genes 10: 261-275.
36. Pagani E, Delbue S, Mancuso R, Borghi E, Tarantini L, Ferrante P. 2003. Molecular analysis of JC virus genotypes circulating among the Italian healthy population. J Neurovirol 9: 559-566.
37. Peters HP, van de Kar NC, Wetzels JF. 2008. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: Report of four cases and review of the literature. Neth J Med 66: 408-415.
38. Pietropaolo V, Di Taranto C, Degener AM, Jin L, Sinibaldi L, Baiocchini A, Melis M, Orsi N. 1998. Transplacental transmission of human polyomavirus BK. J Med Virol 56: 372-376.
39. Pollara CP, Corbellini S, Chiappini S, Sandrini S, De Tomasi D, Bonfanti C, Manca N. 2011. Quantitative viral load measurement for BKV infection in renal transplant recipients as a predictive tool for BKVAN. New Microbiol 34: 165-171.
40. Randhawa PS, Demetris AJ. 2000. Nephropathy due to polyomavirus type BK. N Eng J Med 342: 1309-1315.
41. Rinaldi L, Rinaldi F, Perini P, Calabrese M, Seppi D, Grossi P, Mattisi I, Barzon L, Mengoli C, Sanzari M, Palú G, Gallo P. 2010. No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: An 18 month follow-up study. J Neurol Neurosurg Psychiatry 81: 1345-1350.
42. Rinaldo CH, Hansen H, Traavik T. 2005. Human endothelial cells allow passage of an archetypal BK virus (BKV) strain-A tool for cultivation and functional studies of natural BKV strains. Arch Virol 150: 1449-1458.
43. Rubinstein R, Schoonakker A, Harley EH. 1991. Recurring theme of changes in the transcriptional control region of BK virus during adaptation to cell culture. J Virol 65: 1600-1604.
44. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM. 2005. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: An open-label trial. Arthritis Rheum 52: 501-513.
45. Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN. 2007. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 123: 66-73.
46. Sprangers B, Lefkowitz GI, Cohen SD, Stokes MB, Valeri A, Appel GB, Kunis CL. 2010. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin J Am Soc Nephrol 5: 790-797.
47. Stoner GL, Jobes DV, Cobo MF, Agostini HT, Chima SC, Ryschkewitsch CF. 2000. JC virus as marker of human migration to the Americas. Microbes Infect 2: 1905-1911.
48. Suri M, Tran K, Sharma AP, Filler G, Grimmer J. 2008. Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab. Int Urol Nephrol 40: 807-810.
49. Tremolada S, Delbue S, Larocca S, Carloni C, Elia F, Khalili K, Gordon J, Ferrante P. 2010. Polymorphisms of the BK virus subtypes and their influence on viral in vitro growth efficiency. Virus Res 149: 190-196.
50. Vaz B, Cinque P, Pickhardt M, Weber T. 2000. Analysis of the transcriptional control region in progressive multifocal leukoencephalopathy. J Neurovirol 6: 398-409.
51. Vinai M, Waber P, Seikaly MG. 2010. Recurrence of focal segmental glomerulosclerosis in renal allograft: An in-depth review. Pediatr Transplant 14: 314-325.
52. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC. 2008. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359: 242-251.
53. Warnke C, Adams O, Hartung HP, Kieseier BC. 2011. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 69: 215-216.
54. Yogo Y, Sugimoto C, Zhong S, Homma Y. 2009. Evolution of the BK polyomavirus: Epidemiological, anthropological and clinical implications. Rev Med Virol 19: 185-199.
55. Zhong S, Randhawa PS, Ikegaya H, Chen Q, Zheng HY, Suzuki M, Takeuchi T, Shibuya A, Kitamura T, Yogo Y. 2009. Distribution patterns of BK polyomavirus (BKV) subtypes and subgroups in American, European and Asian populations suggest co-migration of BKV and the human race. J Gen Virol 90: 144-152.